BIORESTORATIVE THERAPIES, INC. financials

BRTX CIK 0001505497

Source: EDGAR filings · Built 2026-06-19T00:35:00Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -10.91M -8.34M -6.60M -6.18M -3.36M
EBITDA -15.44M -11.37M -15.06M -18.85M -26.22M -2.63M
Working Capital -586.03K 7.40M 8.78M 9.15M 21.10M 2.14M
Net Debt -722.06K -1.41M -20.36M 1.73M
Gross Margin 93.37% 93.00% 100.00%
Operating Margin -4350.05% -2881.59% -10439.49% -15838.08% -57191.03% -3574.12%
Net Margin -3959.40% -2239.25% -7145.20% -11036.98% -96311.51% -14639.85%
Return on Equity (ROE) -3992.21% -105.25% -104.13% -128.49% -410.87% 846.62%
Return on Assets (ROA) -349.10% -73.12% -82.60% -80.45% -197.31% -259.32%
Current Ratio 0.84× 2.97× 4.37× 2.53× 59.01× 3.05×
Debt-to-Equity 0.02× 0.03× 0.06× -3.60×
Cash Conversion Ratio 0.76× 0.92× 0.62× 0.45× 0.08× 0.17×
Accruals Ratio -0.85× -0.06× -0.32× -0.44× -1.82× -2.14×
SBC % of Revenue 924.56% 701.39% 5338.11% 10528.27% 50236.86% 898.31%
CapEx Coverage -92.95× -77.51× -37.59× -22.29× -108.61×
Free Cash Flow Per Share $-1.21 $-1.07 $-1.56 $-1.71 $-2.83

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 359.70K 401.00K 145.80K 119.80K 46.00K 77.00K
Cost of Goods and Services Sold 23.84K 28.07K
Gross Profit 335.86K 372.93K 145.80K
Research and Development Expense 10.09M 6.71M 4.03M 3.51M 729.06K 876.83K
Operating Expenses 15.98M 11.93M 15.37M 19.09M 26.35M 2.83M
Operating Income (Loss) -15.65M -11.56M -15.22M -18.97M -26.31M -2.75M
Net Income (Loss) Attributable to Parent -14.24M -8.98M -10.42M -13.22M -44.30M -11.27M
Earnings Per Share, Basic $-1.58 $-1.16 $-2.47 $-3.65 $-37.30
Weighted Average Number of Shares Outstanding, Basic 8.99M 7.76M 4.22M 3.62M 1.19M
Earnings Per Share, Diluted $-1.58 $-1.16 $-2.47 $-3.65
Weighted Average Number of Shares Outstanding, Diluted 8.99M 7.76M 4.22M 3.62M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 1.51M 547.89K 884.38K 1.71M 21.03M
Assets, Current 3.14M 11.14M 11.39M 15.13M 21.47M 3.19M
Assets 4.08M 12.28M 12.61M 16.43M 22.45M 4.35M
Long-term Debt 250.00K
Liabilities, Current 3.72M 3.75M 2.61M 5.98M 363.82K 1.04M
Liabilities 3.75M 2.61M 6.14M 856.50K 5.68M
Stockholders' Equity Attributable to Parent 356.74K 8.53M 10.00M 10.29M 10.78M -1.33M
Common Stock, Shares, Outstanding 8.88M 6.92M 4.71M 3.68M 3.52M 715,544

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -10.79M -8.23M -6.43M -5.91M -3.33M -1.96M
Payments to Acquire Property, Plant, and Equipment 116.07K 106.19K 171.04K 265.22K 30.66K
Net Cash Provided by (Used in) Investing Activities 8.90M 514.53K 3.25M -13.40M -30.66K
Payments for Repurchase of Common Stock 0
Net Cash Provided by (Used in) Financing Activities 2.85M 7.38M 2.35M 21.32M 5.03M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (BRTX CIK 0001505497), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CMTG

Claros Mortgage Trust, Inc.

LSEB

LSEB CREATIVE CORP.

TENX

TENAX THERAPEUTICS, INC.